Insulet Corporation — Q2 2022 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2022. Insulet develops, manufactures and sells the Omnipod insulin delivery system, alongside a smaller drug-delivery business. Figures are in U.S. dollars.
Financial performance
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Total revenue | $299.4m | $263.2m | $594.8m | $515.5m |
| Gross profit | $190.3m | $182.7m | $400.0m | $350.2m |
| Gross margin | 63.6% | 69.4% | 67.2% | Not stated directly |
| Operating income (loss) | $(26.7)m | $26.3m | $11.2m | $42.6m |
| Net income (loss) | $(35.0)m | $(25.0)m | $(7.2)m | $(25.0)m |
| Operating cash flow | Not separately provided for the quarter | $11.6m | $(16.8)m |
- Q2 revenue increased 13.8% reported and 17.7% on a constant-currency basis; six-month revenue rose 15.4% and 18.5%, respectively. Omnipod drove growth, while Drug Delivery declined in Q2.
- Q2 U.S. Omnipod revenue rose 30.5% to $196.4m. International Omnipod revenue fell 2.4% reported but grew 8.9% in constant currency. Drug Delivery revenue declined 35.5% to $13.6m.
- Q2 gross margin fell 580 basis points year over year. The six-month gross margin was 67.2%; management described it as relatively level with the prior year.
- Q2 SG&A rose 50.0% to $174.4m, including $27.3m of legal costs and $3.4m of former-CEO transition costs. Adjusted EBITDA, a non-GAAP measure, was $27.6m versus $52.3m; six-month Adjusted EBITDA was $90.6m versus $87.4m.
Liquidity, debt and balance sheet
- At June 30, cash and cash equivalents were $708.6m, down from $791.6m at year-end 2021. Cash, cash equivalents and restricted cash totaled $723.8m.
- Six-month cash flows: $11.6m provided by operations, $68.8m used in investing and $21.9m used in financing. Cash, cash equivalents and restricted cash decreased $82.6m.
- Total debt, net, was $1,411.5m, including $800.0m of 0.375% convertible notes due 2026 and a $495.0m term loan. The $70.0m revolving facility had no borrowings outstanding. Management said available liquidity should cover projected operating, investing and debt-service needs for at least 12 months.
- Total assets were $2,113.7m and stockholders’ equity was $422.4m. Inventory was $320.4m, up from $303.2m at December 31, 2021.
Changes, outlook and material items
- Revenue growth reflected higher Omnipod volume, pharmacy-channel growth and favorable sales-channel mix. U.S. growth also included higher distributor inventory associated with the Omnipod 5 launch. Related-party revenue was $55.5m in Q2 and $103.9m for six months, versus $3.3m and $5.5m; management attributed the increase primarily to a shift in certain revenue between distributors.
- Management cited supply constraints, supply-chain disruption and inflation. Inventory increases were part of planned supply mitigation. U.S. manufacturing ramp-up, manufacturing inefficiencies, Omnipod 5 costs and higher warranty expense pressured Q2 margin.
- Full-year 2022 gross-margin guidance was 65%–66%. Management expected R&D and SG&A spending to rise year over year, capital expenditures to increase, U.S. Omnipod growth to be strong, International Omnipod revenue to increase, and Drug Delivery revenue to decline. No numerical full-year revenue-growth guidance is provided in the filing text.
- Omnipod 5 received FDA clearance in January for people aged six and older with type 1 diabetes. Limited release began in February; full market release began in August, after quarter-end. European CE Mark review was ongoing.
- In July 2022, Insulet settled Roche patent litigation for a one-time $20m payment; the charge was recorded in Q2 SG&A. It also accrued $5.7m for an unresolved in-licensed intellectual-property contract dispute; settlement proposals ranged from $5.7m to $36m, and the outcome could materially affect results.
- Adoption of ASU 2020-06 increased reported debt and reduced additional paid-in capital; it also lowered non-cash interest expense compared with the prior period. The 2021 comparison included a $40.1m loss on extinguishment of debt.
- Key risks include dependence on the Omnipod platform, competition, reimbursement access, supply-chain and supplier concentration, international execution, regulatory and product-quality matters, intellectual-property disputes, and ability to service debt.
Important facts for investors to verify
- Whether Omnipod 5 full-market launch translates into sustained customer growth, pharmacy sales and reimbursement coverage.
- Whether supply constraints, inflation, manufacturing ramp costs and warranty claims continue to weigh on margins against the 65%–66% full-year target.
- How much reported U.S. growth reflects end-customer demand versus distributor mix and inventory movements, including the unusually higher related-party revenue.
- The final cost and timing of resolving the in-licensed IP dispute, and any further legal or settlement expenses.
- Cash conversion and debt-service capacity as the company funds manufacturing expansion, capital spending and growth initiatives.